<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794455</url>
  </required_header>
  <id_info>
    <org_study_id>VR5642</org_study_id>
    <nct_id>NCT01794455</nct_id>
  </id_info>
  <brief_title>Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression</brief_title>
  <official_title>Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot proposal will test the hypothesis that altered cerebral vessel reactivity and&#xD;
      cerebral hypoperfusion (decreased blood flow to the brain) is a core mechanism underlying the&#xD;
      relationship between vascular disease and depression in older adults. The long-term objective&#xD;
      of this line of research is to: A) determine the relationship between vascular reactivity,&#xD;
      cerebral hypoperfusion and the persistence of late-life depression and B) determine if&#xD;
      improving cerebral perfusion with angiotensin receptor blockers (ARBs) improves depression&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine how magnetic resonance imaging (MRI) measures of cerebral perfusion&#xD;
      relate to antidepressant response. There are two phases to the study. In the first phase, we&#xD;
      will examine how cerebral perfusion is related to response to sertraline, a commonly used&#xD;
      antidepressant. In the second phase, we will examine individuals who do not respond to&#xD;
      sertraline or other selective serotonin reuptake inhibitors (SSRI). We will examine if&#xD;
      candesartan, an ARB, improves depression and if it does so by improving cerebral perfusion.&#xD;
&#xD;
      After providing informed consent, participants will undergo medical and psychiatric&#xD;
      screening. Participants determined to be eligible at the screen will proceed to a baseline&#xD;
      evaluation, which will include brief cognitive neuropsychological testing and MRI.&#xD;
      Participants will then begin open-label sertraline for eight weeks (baseline to week 8).&#xD;
      Dosing will begin at 50mg daily and, based on response and tolerability, can increase up to&#xD;
      the FDA approved maximum dose of 200mg daily.&#xD;
&#xD;
      After the eight weeks, participants will be re-evaluated and complete another MRI. Those who&#xD;
      respond to sertraline and experience remission of their depression will end their study&#xD;
      participation. Those who do not experience remission will continue to the phase 2 open-label&#xD;
      candesartan arm.&#xD;
&#xD;
      The candesartan arm will last for 12 weeks (week 8 to week 20). Dosing will begin at 4mg&#xD;
      daily and can increase to a maximum dose of 32mg, based on tolerability and response.&#xD;
      Participants will be monitored closely, and other antihypertensive medications adjusted to&#xD;
      avoid low blood pressure. At the end of the 12-week trial, participants will again complete&#xD;
      MRI and neuropsychological testing. Their study participation will then end.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment difficulties&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Arterial Spin Labeling</measure>
    <time_frame>Change in perfusion from baseline to week 8</time_frame>
    <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Week 8</time_frame>
    <description>MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</measure>
    <time_frame>Week 8</time_frame>
    <description>Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</measure>
    <time_frame>Week 20</time_frame>
    <description>Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale</measure>
    <time_frame>Week 20</time_frame>
    <description>MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Arterial Spin Labeling</measure>
    <time_frame>Change from week 8 to week 20</time_frame>
    <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Depression</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Phase 1: Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50mg - 200mg daily</description>
    <arm_group_label>Phase 1: Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>4mg - 32mg daily</description>
    <arm_group_label>Phase 2: Candesartan</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 60 years or older&#xD;
&#xD;
          2. Diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic&#xD;
             features by Diagnostic and Statistical Manual IV Text Revision (DSMIV-TR) criteria&#xD;
&#xD;
          3. Presence of hypertension (defined as systolic &gt; 140 or diastolic &gt; 90 or currently&#xD;
             receiving antihypertensive therapy)&#xD;
&#xD;
          4. Minimum depression severity of ≥ 15 on the Montgomery-Asberg Depression Rating Scale&#xD;
             (MADRS)&#xD;
&#xD;
          5. Cognitively intact or with mild cognitive deficits, with a minimum score ≥ 23 on the&#xD;
             Montreal Cognitive Assessment (MoCA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other psychiatric Axis I disorders&#xD;
&#xD;
          2. Acute suicidality&#xD;
&#xD;
          3. Electroconvulsive therapy in the last 6 months&#xD;
&#xD;
          4. Primary neurological disorder, including dementia and stroke&#xD;
&#xD;
          5. Significant cardiovascular disease, specifically diagnosis of congestive heart&#xD;
             failure, known bilateral renal artery stenosis, symptomatic hypotension, or critical&#xD;
             aortic or mitral stenosis&#xD;
&#xD;
          6. Myocardial infarction or open-heart surgery in last 6 weeks&#xD;
&#xD;
          7. Serum creatinine ≥ 265 micromol /L&#xD;
&#xD;
          8. Serum potassium ≥ 5.5 mmol/L&#xD;
&#xD;
          9. MRI contraindications&#xD;
&#xD;
         10. Known allergy to sertraline or candesartan specifically or known allergy to other&#xD;
             SSRIs or ARBs.&#xD;
&#xD;
         11. History of prolonged (&gt; 3 weeks) or self-described severe discontinuation syndrome in&#xD;
             the past after stopping an antidepressant.&#xD;
&#xD;
         12. Current use of an angiotensin receptor blocker&#xD;
&#xD;
         13. Current or planned psychotherapy&#xD;
&#xD;
         14. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge&#xD;
             would be contraindicated or put the subject at increased risk. This would include&#xD;
             acute respiratory disease, chronic angina, or other unstable cardiac conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren D Taylor, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Psychiatric Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <results_first_submitted>July 18, 2016</results_first_submitted>
  <results_first_submitted_qc>August 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2016</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Warren Taylor</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Depressive Disorder</keyword>
  <keyword>Geriatrics</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Sertraline</title>
          <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
        </group>
        <group group_id="P2">
          <title>Phase 2: Candesartan</title>
          <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Sertraline</title>
          <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
        </group>
        <group group_id="B2">
          <title>Phase 2: Candesartan</title>
          <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="67" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="B3" value="67" lower_limit="67" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI Arterial Spin Labeling</title>
        <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.</description>
        <time_frame>Change in perfusion from baseline to week 8</time_frame>
        <population>Could not complete MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Arterial Spin Labeling</title>
          <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.</description>
          <population>Could not complete MRI.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
        <description>Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
          <description>Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
        <description>Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.</description>
        <time_frame>Week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
          <description>Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Asberg Depression Rating Scale</title>
        <description>MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.</description>
        <time_frame>Week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale</title>
          <description>MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Arterial Spin Labeling</title>
        <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.</description>
        <time_frame>Change from week 8 to week 20</time_frame>
        <population>MRI data could not be obtained on the one study participant due to MRI contraindications.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Arterial Spin Labeling</title>
          <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.</description>
          <population>MRI data could not be obtained on the one study participant due to MRI contraindications.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: Sertraline</title>
          <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.&#xD;
Sertraline: 50mg - 200mg daily</description>
        </group>
        <group group_id="E2">
          <title>Phase 2: Candesartan</title>
          <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.&#xD;
Candesartan: 4mg - 32mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was ended early due to difficulty with subject recruitment. MRI data could not be obtained on that one individual due to MRI contraindications.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Warren Taylor</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-936-3555</phone>
      <email>warren.d.taylor@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

